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cardiopulmonary resuscitation have limited
effects on myocardial blood flow: a randomized
porcine study
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David Zughaft1, David Erlinge1 and Göran K Olivecrona1Abstract
Background: In current guidelines, prolonged cardiopulmonary resuscitation (CPR) mandates administration of
repeated intravenous epinephrine (EPI) doses. This porcine study simulating a prolonged CPR-situation in the
coronary catheterisation laboratory, explores the effect of EPI-administrations on coronary perfusion pressure (CPP),
continuous coronary artery flow average peak velocity (APV) and amplitude spectrum area (AMSA).
Methods: Thirty-six pigs were randomized 1:1:1 to EPI 0.02 mg/kg/dose, EPI 0.03 mg/kg/dose or saline (control)
in an experimental cardiac arrest (CA) model. During 15 minutes of mechanical chest compressions, four
EPI/saline-injections were administered, and the effect on CPP, APV and AMSA were recorded. Comparisons were
performed between the control and the two EPI-groups and a combination of the two EPI-groups, EPI-all.
Result: Compared to the control group, maximum peak of CPP (Pmax) after injection 1 and 2 was significantly
increased in the EPI-all group (p = 0.022, p = 0.016), in EPI 0.02-group after injection 2 and 3 (p = 0.023, p = 0.027)
and in EPI 0.03-group after injection 1 (p = 0.013). At Pmax, APV increased only after first injection in both the EPI-all
and the EPI 0.03-group compared with the control group (p = 0.011, p = 0.018). There was no statistical difference of
AMSA at any Pmax. Seven out of 12 animals (58%) in each EPI-group versus 10 out of 12 (83%) achieved spontaneous
circulation after CA.
Conclusion: In an experimental CA-CPR pig model repeated doses of intravenous EPI results in a significant increase in
APV only after the first injection despite increments in CPP also during the following 2 injections indicating inappropriate
changes in coronary vascular resistance during subsequent EPI administration.
Keywords: Cardiac arrest, Mechanical chest compressions, EpinephrineBackground
Routine use of epinephrine (EPI) during cardiopulmonary
resuscitation (CPR) was first described in the early 1960-
ies [1] and has ever since been recommended in guidelines
during advanced CPR. Current guidelines recommend
administration of 1 mg of EPI given intravenously every
3 – 5 minute Class IIb (LOE A) [2,3]. Several clinical
studies and randomized trials have reported an increased
frequency of return of spontaneous circulation (ROSC) in* Correspondence: henrik.wagner@med.lu.se
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unless otherwise stated.out-of-hospital cardiac arrest (OHCA) after various dos-
ages of repeated EPI administrations [4-7]. However, the
increased frequency of ROSC does not convey improve-
ments in discharge from hospital in good neurological
condition or long term survival [4,7,8].
Both experimental and clinical studies have shown a
higher frequency of ROSC when the coronary perfusion
pressure (CPP) can be brought to a level > 15 mmHg
before defibrillation during CPR-treatment [9-13]. Both
increments in CPP and myocardial creatine phosphate are
associated with altered ventricular fibrillation (VF) wavelets
that in turn increase the possibility of a successful CPRl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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quantitative combined measure of the electrical activity
of VF wavelets, that seems to be a predictor of defibril-
lation success [15] and other experimental studies have
shown a correlation between CPP, AMSA, and defibril-
lation success [13,16].
A Doppler flow wire can be used to measure coronary
blood flow in patients with a stable circulation [17-19],
and experimentally a good correlation has been demon-
strated between CPP and the average blood flow (APV)
in a coronary vessel assessed by a Doppler flow wire during
mechanical chest compressions (MCC) [20].
Previous experimental studies have evaluated the
effects of repeated doses of EPI on CPP [21,22], VF-
amplitude [23] and myocardial blood flow [24] during
CPR, but all these studies have been designed to reflect
the OHCA situation. The aim of this study was to assess
CPP, coronary artery APV reflecting myocardial pressure
and perfusion in addition to AMSA (reflecting bioelec-
trical activity) during CA caused by VF in an experimental
situation adopted to the catheterisation laboratory setting,
which includes a shorter untreated VF time and prolonged
need for CPR while performing PCI [25].
Methods
The study conformed to the guide for the care and use of
laboratory animals, US National Institute of Health (NIH
Publication No. 85-23, revised 1996) and was approved by
the Malmö/Lund Committee for Animal Experiment
Ethics, Dnr M 192-10.
Animal preparation and monitoring
Thirty-six Swedish-bred (Swedish Landrace) pathogen free
pigs with a mean weight of 38 kg (SD ± 4.1, range 32 -
46 kg) were included. The pigs were fasted overnight with
free access to water. At the day of the experiment
they were pre-medicated with Ketaminol 150 mg/10 kg
(Ketamine 100 mg/ml, Intervet, Danderyd, Sweden) and
Rompun 20 mg/10 kg intramuscularly (Xylazin 20 mg/ml,
Bayer AG, Leverkusen, Germany). After induction of
anaesthesia with thiopental 12.5 mg/kg/dose (Pentothal
100 mg/ml Abbott, Stockholm, Sweden) the animals
were orally intubated with cuffed endotracheal tubes.
To maintain anaesthesia, a slow infusion of (Fentanyl
1.25 μg/ml (Fentanyl Pharmalink AB, Stockholm, Sweden)
in buffered glucose (25 mg/ml) was started at a rate of
2 ml/min and adjusted as needed. During the anaesthe-
sia, meprobamat (Mebumal DAK Copenhagen Denmark)
and/or thiopental was titrated if needed in small bolus
doses. The animals were ventilated with a mixture of ni-
trous oxide (70%) and oxygen (30%) and normal air using
a mechanical Siemens-Elema 900B ventilator (Siemens
Elema Solna, Sweden) in the volume-controlled mode,
adjusted in order to obtain normoventilation maintainingend tidal carbon dioxide at 4.5 - 5.5 kPa. In addition, the
animals were monitored with a three lead electrocar-
diogram using an IntelliVue MP90 monitoring system
(Philips, Eindhoven, The Netherlands). A 6 F FL3.5 diag-
nostic catheter (Boston Scientific Scimed, Maple Grove,
MN, USA) was introduced through the left carotid artery
into the ostium of the left main coronary artery. This
catheter was used to place a 0.014-inch, 12 MHz pulsed
Doppler flow velocity transducer (FloWire® Volcano Inc.,
San Diego, CA, USA) into the mid-portion of the left
anterior descending artery (LAD). A 7.5 F Continuous
Cardiac Output Pulmonary Artery Catheter™ (Edwards
Lifesciences, Irvine, CA, USA) was inserted through the
surgically exposed right jugular vein. Central venous pres-
sure (CVP) was measured in the right atria via a separate
transducer. A 6 F pig-tail catheter was placed in the as-
cending aorta for arterial blood pressure (ABP) measure-
ment. Ten-thousand units of un-fractioned heparin (LEO
Pharma AB, Malmoe Sweden) was given intravenously at
the start of the catheterisation. The procedures were per-
formed in an experimental catheterization fluoroscopy
laboratory (Shimadzu Corp., Kyoto, Japan).
Experimental protocol
A flow chart of the experiment is presented in Figure 1.
Pigs were randomized using sealed envelopes. The person
opening the envelope prepared the prescribed drug while
the remainder of the researchers were blinded to the drug
administered during the experiment. The animals received
EPI 0.02 mg/kg/dose as previously described in a study by
Pytte et al [26] or 0.03 mg/kg/dose as described in a study
by Ristagno et al [27] or saline (control). Each syringe was
diluted to a total of 10 ml. After preparation and a base-
line period, VF was induced using a 9 V direct current
(Duracell Battery, Procter & Gamble, Cincinnati OH,
USA) between a skin electrode and an intracardiac needle
inserted to the epicardium with a stimulation time be-
tween 5 – 10 seconds, resulting in an instant loss of ABP
and LAD flow. After one minute of untreated VF, MCC
and manual ventilation at a rate of 8 – 10 inflations/mi-
nute with 100% of oxygen was started and continued for
15 min prior to defibrillation. For standardized chest com-
pressions an electrically driven MCC device was used
(LUCAS™2, Physio-Control/Jolife AB, Lund, Sweden). At
5, 8, 11 and 14 minutes after VF-induction an injection of
the allocated drug/saline was administered followed by
a flush of 10 ml NaCl via a peripheral cannula in a vein
in the ear. The rationale behind a 16 minute VF period
(1 minute of untreated VF followed by 15 minutes of
MCC) was an attempt to reflect a CA situation in the
human cardiac catheterisation laboratory with prolonged
advanced CPR in connection with PCI [25].
After 15 minutes of VF and MCC, the first defibrilla-
tion (LIFEPAK 12 Defibrillator/Monitor, Physio-Control,
Figure 1 Experimental time line. MCC =mechanical chest compressions, VF = ventricular fibrillation, CPR = cardiopulmonary resuscitation,
EPI = epinephrine, defib = defibrillation, min =minutes, ROSC = return of spontaneous circulation, Drug administration; either 0.02 mg EPI/kg/dose
or 0.03 mg EPI/kg/dose or NaCl , was administrated after 4 minutes of MCC and then every 3rd minute during the 15 minutes of MCC.
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obtained, a fifth dose of EPI was given and repeated defi-
brillations were performed as needed for a total of 3
times, with 2-minute intervals during MCC. ROSC was
defined as a stable circulation with an ABP > 60 mmHg
for 15 minutes after defibrillation. After 15 minutes of
ROSC the animals were euthanized with 40 mmol potas-
sium injected into the pulmonary artery catheter.
Measurements and analysis
Arterial blood pressure and CVP were continuously
measured using a sampling rate at 1000 Hz (AD Instru-
ments Inc, Colorado Springs, CO, USA). Hemodynamic
parameters were digitally recorded using Chart v4.2 (AD
Instruments Inc, Colorado Springs, CO, USA). Coronary
perfusion pressure was calculated as the difference be-
tween the arterial-end diastolic pressure and the venous
right atrial-end diastolic pressure [28]. The maximum
peak of CPP (Pmax) was depicted at 20, 60, 120, 180 sec-
onds after initiation of MCC, at the time of every EPI
injection and when CPP reached the highest value after
each injection. In the control group CPP was depicted
90 seconds after each saline injection. Continuous coron-
ary APV were displayed and recorded using the Doppler
flow wire connected to a FloMap monitor (Cardiometrics,
Mountain View, CA). The APV was analysed in visual
artefact free zones concomitantly with Pmax.
Analog ECG signals were digitized and converted
from a time to a frequency domain by fast Fourier
transformation at a sampling rate of 250 Hz. Ampli-
tude spectrum area was calculated as the sum of the
products of individual frequencies between 8 and 48 Hz at
Pmax. The measurements were performed throughout
the 16 minutes of VF as median values of every
10 second period. Time to Pmax were analyzed in the
EPI-groups. Survival was defined as stable ROSC for
15 min post successful defibrillation and assessed in
each group.
All analyses of these parameters were performed on
the three groups and on a merged group including the
two EPI-groups (EPI-all).Statistics
Analyses were performed comparing data in the control
group with those of each EPI dose group and a combin-
ation of the 2 EPI-groups. Continuous variables are pre-
sented as their mean ± SD or median and 25th to 75th
interquartile. Categorical values are presented as numbers
and percentages. Fisher’s exact test was used for compar-
ing categorical variables. The Mann-Whitney U test was
used for comparing unpaired continuous variables. The
Kruskal – Wallis test was used to compare multiple me-
dian values when time to peak maximum was compared.
Results
No difference was seen during the baseline period regard-
ing analysed measurements between any groups (Table 1).
CPP
During the first 4 minutes of MCC and at the time of the
first EPI injection, there were no significant differences in
CPP between the control group (n = 12), EPI-all group
(n = 24), EPI 0.02 mg/kg/dose (n = 12) or EPI 0.03 mg/
kg/dose (n = 12). During the following period of MCC
there was a significant increase in CPP at Pmax after EPI
injection 1 and 2 in the EPI-all group (p = 0.022, p = 0.016),
compared to the control group but not after injection 3
and 4. We found a significant increase in CPP after in-
jection 2 and 3 in EPI 0.02 mg/kg/dose compared to the
control group (p = 0.023, p = 0.027). When comparing
EPI 0.03 mg/kg/dose to the control group there was a
statistical significant difference at Pmax following injec-
tion 1 (p = 0.013) but not at Pmax following injection 2, 3
and 4 (Table 2, Figure 2a).
APV
During the first 4 minutes of VF there were no statisti-
cally significant differences in APV between any groups.
During the following period of MCC there was a signifi-
cant increase in APV after injection 1when comparing
the control group to the EPI-groups except for EPI
0.02 mg/kg/dose group, in which the APV increase was
only borderline (p = 0.056). We could not detect any
Table 1 Baseline parameters
NaCl (n = 12) EPI all (n = 24) P-value EPI 0.02 mg/kg/dose
(n = 12)
P-value EPI 0.03 mg/kg/dose
(n = 12)
P-value
Syst ABP 152 (137 - 167) 151 (136 - 163) 0.5347 149 (136 - 172) 0.4357 152 (136 - 172) 0.7950
Diast ABP 96 (79 - 122) 96 (89 - 106) 0.6996 93 (89 - 99) 0.7075 100 (78 - 107) 0.7950
Mean ABP 115 ( 99 - 139) 114 (105 - 124) 0.5347 113 (105 - 118) 0.5067 116 (954 - 126) 0.7075
Max CVP 12 (10 - 13) 11 (10 -13) 0.6505 11 (10 - 13) 0.5444 11 (10 -13) 0.8852
Min CVP 8 (5 - 10) 7 (6 - 8) 0.4502 7 (4 - 8) 0.2855 7 (6 - 9) 0.8399
Mean CVP 10 (8 - 11) 9 (8 - 11) 0.7944 9 (8 - 11) 0.7350 9 (8 - 11) 0.9310
ETCO2 4.9 (4.3 - 5.0) 4.5 (4.1 - 4.9) 0.5642 4.8 (4.4 - 5.0) 0.8691 4.3 (4.0 -4.7) 0.2727
APV 17 (12 - 28) 17 (12 - 24) 0.7677 20 (13 - 26) 0.8399 15 (11 - 21) 0.4417
Heart rate 88 (58 - 97) 75 (64 - 91) 0.7455 77 (71 - 93) 0.8955 71 (56 - 90) 0.4701
pH 7.473 (7.420-7.505) 7.484 (7.402-7.510) 0.9331 7.468 7.414-7.529) 0.7950 7.485 (7.3875-7.503) 0.6650
PCO2 5.3 (5.0-6.5) 5.4 (5.1-5.9) 0.7246 5.5 (5.1-5.9) 0.9310 5.2 (4.9-5.9) 0.6236
PO2 27.2 (16.6-37.1) 20.2 (17.2-33.9) 0.6030 23.0 (17.3-33.2) 0.8174 20.2 (16.4-33.9) 0.5254
ABE 6.0 (4.6-7.3) 5.9 (2.8-7.8) 0.9065 6.8 (3.2-8.7) 0.7075 5.5 (2.5-6.1) 0.2855
NaCl = Saline, EPI = epinephrine, Syst = Systolic, ABP = arterial blood pressure (mmHg), Diast = Diastolic, Max =maximum.
CVP = central venous pressure (mmHg), Min =minimum, ETCO2 = end tidal carbon dioxide (kPa), APV = average peak velocity (cm/s).
Heart rate (beats/minute), PCO2 = partial pressure carbon dioxide, (kPa), PO2 = partial pressure oxygen (kPa).
ABE = arterial base excess (mmol/l). All values are expressed as median, 25th and 75th interquartile.
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(Table 3, Figure 2b).
AMSA
There were no statistical differences in AMSA, when
comparing the control group to any of the EPI-groups.
(Table 4, Figure 2c).
Time to maximum peak of CPP
The median time to Pmax following the EPI injections
was 50 (interquartile range 48 to 52) seconds (Table 5).
There were no significant difference in time to PmaxTable 2 Physiological values of CPP during 15 minutes of MC
CPP NaCl (n = 12) CPP EPI all (n = 24) P-value
MCC 20 s 30 (23-42)a 27 (12-40)e 0.4141
MCC 60 s 31 (23-36)a 25 (16-45)d 0.9331
MCC 120 s 28 (14-36)a 27 (9-47)e 0.7152
MCC 180 s 29 (14-39)a 27 (13-42)f 0.8712
Inj #1 29 (10-40)b 27 (11-49)n 0.9368
Peak #1 29 (11-41)c 44 (31-78)e 0.0219
Inj #2 29 (15-41)b 25 (16-38)e 1.0000
Peak #2 28 (12-36)c 39 (31-59)e 0.0160
Inj #3 32 (18-35)c 27 (11-36)d 0.9849
Peak #3 28 (10-38)c 39 (29-50)e 0.1434
Inj # 4 31 (21-32)b 26 (12-38)f 0.9848
Peak #4 24 10-37)c 32 (24-45)e 0.1894
CPP = Coronary perfusion pressure (mmHg), NaCl = Saline, EPI = epinephrine, MCC =
d: n = 24, e: n = 23, f: n = 22, g: n = 21. Peak values at 20 , 60, 120, 180 seconds after
after start of MCC) and the corresponding peak to each injection for NaCl comparebetween the EPI-groups following injection 1 to 4
(Table 5).
ROSC
Return of spontaneous circulation was achieved in 10/12
(84%) animals in the control group compared with 7/12
(58%) in each EPI-group (p = 0.37).
Discussion
This study shows that intravenous administration of
recommended doses of EPI during prolonged advanced
CPR with MCC increases the perfusion pressure in theC-time
CPP EPI 0.02 mg/kg/
dose (n = 12)
P-value CPP EPI 0.03 mg/
dose (n = 12)
P-value
28 (12-46)b 0.7818 26 (18-37)a 0.2855
34 (14-46)a 0.6650 25 (21-46)a 0.7950
25 (16-49)b 0.5588 29 (25-52)b 0.6891
25 (14-44)b 1.0000 29 (21-53)c 0.9737
31 (11-48)b 0.9476 27 (14-57)c 0.9719
38 (28-78)b 0.1489 47 (39-77)a 0.0134
19 (10-44)a 0.6009 27 (24-50)b 0.5545
50 (31-65)a 0.0229 37 (29-56)b 0.0620
12 (7-38)a 0.6209 27 (25-39)a 0.6682
42 (32-50)a 0.0265 35 (28-64)a 0.1213
13 (11-43)c 0.5974 27 (23-39)a 0.6891
32 (22-47)b 0.2453 33 (29-44)a 0.2766
Mechanical chest compressions, Inj = injection, a: n = 12, b: n = 11, c: n = 10,
start of MCC, at each time point of the 4 drug injections (4, 7, 10, 13 minutes
d to EPI. All values are expressed as median, 25th and 75th interquartile.
Figure 2 Peak maximum development of coronary perfusion pressure, coronary artery average peak blood flow velocity and amplitude
spectrum area. a = Development of CPP in the combined group, (0.02 mg EPI/kg/dose and 0.03 mg EPI/kg/dose) compared to control group (NaCl)
during the MCC-period (15 min). Significant difference between EPI-group compared to control group, * = p <0.05. b = Development of APV in the
combined group, (0.02 mg EPI/kg/dose and 0.03 mg EPI/kg/dose) compared to control group (NaCl) during the MCC-period (15 min). Significant
difference between EPI-group compared to control group, * = p <0.05. c = Development of AMSA in the combined group, (0.02 mg EPI/kg/dose and
0.03 mg EPI/kg/dose) compared to NaCl during the MCC-period (15 min). EPI = epinephrine, NaCl = saline, CPP = coronary perfusion pressure (mmHg),
inj = injection number 1- 4, Peak 1 – 4 corresponding to injection 1 - 4, APV = average peak velocity (cm/s), AMSA = amplitude spectrum area (mV · Hz).
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seems to be weakened after three out of four injections
when compared to controls. We also found, that the
increase in CPP only transfers into an increase in APV
after the first injection of EPI and no effect could be detec-
ted in AMSA. Human studies have shown that adminis-
tration of EPI according to guidelines recommendations
has a positive effect to attain ROSC but a worse neuro-
logical/survival outcome at discharge from hospital [8,29].
This has also been observed when using higher cumula-
tive doses of EPI [4]. In the present study, numerically
fewer animals receiving EPI obtained ROSC compared to
the control group, although the difference was not signifi-
cant. Larger studies are needed to demonstrate a possible
negative effect on survival of repeated intravenous
EPI-doses during CPR.
In this study median time to Pmax was 50 (48 – 52)
seconds. Pytte et al showed a median time to peak after53 seconds with MCC with a CC-depth at 45 mm and
after 83 seconds with manual CC according to guidelines
from 2005 [26]. Thus both studies support a better circu-
lation in terms of time to peak of CPP created by MCC.
In addition to an adequate CPP, myocardial perfusion
is dependent on coronary artery flow velocity. In a previ-
ous study it was shown that APV was highly correlated
to CPP during prolonged CPR with MCC [20], a study
that was conducted without administration of EPI. In
another study Mayr et al demonstrated that repeated
injections of vasopressin resulted in an increased coron-
ary blood flow in pigs with induced VF circulated with a
cardio-pulmonary bypass technique in a low flow state
[30]. Brown et al showed that high doses of EPI elevated
myocardial blood flow to a higher extent compared with
standard doses [24]. In our study we could only detect a
significant rise in APV after the first EPI injection. Thus,
the increase in CPP after EPI-injection 2 and 3 was not
Table 3 Physiological values of APV during 15 minutes of MCC-time
APV NaCl (n = 12) APV EPI all (n = 24) P-value APV EPI 0.02 mg/kg/dose
(n = 12)
P-value APV EPI 0.03 mg/kg/EPI
(n = 12)
P-value
MCC 20 s 19 (12-28)a 18 (12-22)h 0.3571 20 (13-24)a 0.5444 16 (11-32)b 0.3401
MCC 60 s 20 (15-29)a 20 (11-24)h 0.4141 21 (12-25)a 0.8399 17 (10-22)b 0.2071
MCC 120 s 17 (12-25)a 14 (9-21)h 0.3220 14 (10-21)a 0.4025 10 (8-21)b 0.3401
MCC 180 s 24 (17-29)a 17 (11-26)g 0.0901 14 (10-30)a 0.0606 18 (12-24)b 0.1316
Inj #1 13 (12-20)c 16 (8-20)m 0.8536 16 (9-20)e 0.9646 14 (7-25)e 0.6893
Peak #1 11 (9-15)c 19 (15-26)j 0.0109 19 (12-23)e 0.0561 19 (15-42)b 0.0183
Inj #2 12 (8-18)e 12 (9-20)i 0.8262 10 (8-16)b 0.5915 15 (12-21)b 0.2303
Peak #2 16 (6-19)e 17 (13-31)l 0.1899 18 (13-36)d 0.1629 15 (13-35)e 0.4309
Inj #3 13 (11-20)d 14 (7-22)k 0.5892 16 (9-26)c 0.9674 12 (7-18)e 0.3606
Peak #3 13 (9-22)b 19 (14-31)j 0.5892 19 (15-29)a 0.1661 19 (14-33)f 0.3191
Inj # 4 15 (9-20)b 17 (9-21)j 0.9314 19 (8-29)d 0.8792 16 (10-21)c 1.0
Peak #4 12 (8-21)b 15 (10-29)m 0.6749 14 (12-22)e 0.6497 17 (8-37)e 0.8365
APV = Average peak velocity (cm/s), NaCl = Saline, EPI = epinephrine, MCC =mechanical chest compressions, Inj = injection, a: n = 12, b: n = 11, c: n = 10, d: n = 9,
e: = 8, f: n = 7, g: n = 24, h: n = 23, i: n = 21, j: n = 19, k: n = 18, l: n = 17, m: n = 16. Peak values at 20 , 60, 120, 180 seconds after start of MCC, at each time point of
the 4 drug injections (4, 7, 10, 13 minutes after start of MCC) and the corresponding peak to each injection for NaCl compared to EPI. All values are expressed as
median, 25th and 75th interquartile.
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ing a rise in local vascular resistance and a lesser amount
of oxygenated blood reaching the myocardium, corre-
sponding to the findings of Brown et al using standard
doses of EPI. The different circulation techniques and
ventilation rates used in these studies may have signi-
ficant impact on differences in their results. Still, the
importance to keep CPP at a high level may be ques-
tioned, since the elevated pressure values caused by
EPI in 3 out of 4 injections was not accompanied by an
increase in APV.
Amplitude spectrum area has been associated with a
high positive and negative predictive value to obtain aTable 4 Physiological values of AMSA during 15 minutes of M
AMSA NaCl AMSA EPI All P-value AMSA EPI
MCC 20 s 12.1 (9.6-14.0)b 13.0 (10.9-16.0)d 0.4099 13.0
MCC 60 s 12.4 (10.8-15.3)b 14.4 (11.4-16.8)d 0.4990 13.7
MCC 120 s 13.8 (12.1-16.3)b 16.0 (14.2-18.7)d 0.1974 16.0
MCC 180 s 14.7 (13.3-17.9)b 17.0 (12.8-19.0)d 0.3749 17.0
Inj #1 14.3 (12.7-16.8)b 15.9 (13.9-16.7)d 0.4725 15.4
Peak #1 14.7 (11.5-15.9)b 14.6 (13.0-16.2)d 0.6121 14.6
Inj #2 13.9 (11.0-15.4)b 14.0 (11.6-14.5)d 0.8824 14.3
Peak #2 13.5 (10.4-14.7)b 12.5 (11.0-14.6)d 1.0000 13.1
Inj #3 13.7 (11.4-14.8)b 11.5 (9.7-13.8)d 0.2285 11.5
Peak #3 12.7 (10.6-15.5)b 12.5 (11.1-14.5)d 0.9831 13.1
Inj # 4 13.9 (11.3-15.3)b 11.0 (9.7-13.5)d 0.1696 11.8
Peak #4 14.0 (11.4-15.3)e 11.0 (8.9-15.9)d 0.8841 16.8
AMSA= amplitude spectral area (mV · Hz), NaCl = saline, EPI = epinephrine, MCC =Mec
e: n = 6. Peak values at 20 , 60, 120, 180 seconds after start of MCC, at each time p
corresponding peak to each injection for NaCl compared to EPI. All values are expsuccessful defibrillation in both experimental and human
studies [31,32]. In one study the analyses were performed
only on data from defibrillators used in CA-cases, no
other information about CPR-time or administered EPI
during the resuscitation were recorded [32], rendering
further comparisons difficult to our experimental study.
Furthermore, human and experimental studies have
shown that a CPP above 15 mmHg markedly increases
the possibility to attain ROSC following defibrillation
[9,10]. Hence, to strive towards a CPP above 15 mmHg
during CPR in order to attain ROSC seems logical. Several
experimental studies have shown that an EPI-induced ele-
vation of CPP leads to a higher probability of subsequentCC-time
0.02 mg/kg/dose P-value AMSA EPI 0.03 mg/kg/dose P-value
(11.8-13.0)c 0.3913 13.1 (10.6-15.0)a 0.5752
(10.8-17.6)c 0.7751 14.6 (13.0-15.8)a 0.4288
(14.2-19.8)c 0.1779 15.5 (13.8-17.6)a 0.3734
(12.8-19.3)c 0.4877 17.0 (15.3-18.3)a 0.4288
(9.7-16.7)c 0.4142 16.1 (13.3-16.7)a 0.6682
(13.8-15.9)c 0.7133 14.7 (12.7-16.2)a 0.6444
(13.0-14.9)c 0.7751 13.8 (11.6-14.3)a 0.6209
(11.9-17.5)c 0.5956 12.2 (10.4-13.9)a 0.6682
(10.2-20.9)c 0.5676 11.2 (9.5-11.7)a 0.1616
(10.2-20.9)c 0.5954 12.2 (11.3-14.3)a 0.7169
(10.5-14.3)c 0.6534 10.6 (8.8-12.2)a 0.0806
(9.9-11.1)c 0.3165 9.9 (8.8-14.3)a 0.2814
hanical chest compressions, Inj = injection, a: n = 12, b: n = 10, c: n = 9, d: n = 21,
oint of the 4 drug injections (4, 7, 10, 13 minutes after start of MCC) and the
ressed as median, 25th and 75th interquartile.
Table 5 Time to peak
Inj #1 Inj #2 Inj #3 Inj #4 P-value
Epinephrine all 51 (32-66)c 53 (41-58)c 49 (41-70)c 56 (44-78)c 0.392
Epinephrine 0.02 mg/kg/dose 48 (39-49)b 48 (40-52)a 52 (50-60)a 47 (43-59)b 0.440
Epinephrine 0.03 mg/kg/dose 48 (38-60)a 51 (40-56)b 51 (46-62)b 49 (44-65)a 0.440
Time duration from drug administration to peak time (seconds) /Pmax of CPP for the 4 different drug injections. Inj = Injection, mg=milligram, kg = kilogram, a; n = 12,
b; n = 11, c; n = 23. All Values are expressed as median, 25th and 75th interquartile.
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In studies investigating repeated injections of EPI,
Bar-Joseph et al showed a significant increase in CPP
only after the first injection of repeated doses of high
dose EPI (0.1 mg/kg) [22], and Cairns et al showed a
significant increase in CPP only in the animals who
attained ROSC after first EPI injection followed by
defibrillation [21]. We found a significant increase of
CPP in 3 out of 4 injections, however less pronounced
after injection 2 and 3. The studies by Bar-Joseph et al and
Cairns et al used longer periods of untreated VF-period
simulating OHCA, higher doses of EPI and defibrillation
attempts after each injection of EPI [21,22]. Our goal was
to simulate a frequently occurring situation in the coron-
ary catheterisation laboratory, with a short period of
untreated VF, followed by repeated administrations of EPI
in conjunction with defibrillation and resistant VF. As
opposed to the previous studies we administrated doses
of EPI which were closer to those recommended in the
guidelines. In addition, the different periods of untreated
VF time in, previous experimental settings may influence
the metabolic status and consumption of endogenously
produced EPI in the animals at the initiation of CPR,
which in turn may affect the response to EPI. We also
used slightly different CC-techniques and ventilation rates
[21,22], which also may affect the distribution and effect
of administered drugs.
In regards to cardiac pressure and their influence on
the bioelectrical activity during VF a high CPP correlates
to a high AMSA in some studies [13,16]. Similar to our
study, Achleitner et al showed an elevated mean fibrilla-
tion frequency and VF mean amplitude, during basic life
support [23]. On the contrary, AMSA showed an insig-
nificant tendency to decline in the EPI-groups in our
study despite an increase in CPP, similar to previous
findings [23]. Despite different CPR models and EPI dos-
ages, the results in AMSA were similar in previous study
[23] compared to current study. In the present study EPI
was unable to induce a rise in AMSA, despite increased
CPP and therefore it contributed to a successful defi-
brillation in only 7 out of 12 animals in each EPI-
group. A possible explanation for this result may be an
increased resistance resulting in a decreased myocardial
microcirculatory blood flow induced by EPI, which hasalso been described in capillaries of the brain [34]. The
lack of effects on AMSA following the repeated doses of
EPI may accordingly be a result of a successively dimin-
ished myocardial tissue perfusion caused by EPI through-
out the experiment. Thus, the initial injections of EPI may
serve a purpose, but repeated injections may not be bene-
ficial and may in fact be detrimental in subjects with VF
who are reasonably circulated with manual CC or MCC.
Further research is needed to determine the optimal dos-
ages and frequency of EPI-injections during CPR.
Limitations
The experimental set up primarily reflects a very specific
in-hospital CA scenario including a prompt response to
a CA with CC followed by a prolonged CPR situation,
for instance in the catheterisation laboratory with a ther-
apy resistant VF and MCC. Since the animals were young,
healthy and without coronary artery disease, it may be dif-
ficult to extrapolate our findings into an unselected pa-
tient category suffering CA. The study was not powered
to evaluate differences in survival. EPI was administered
according to guidelines, and the results should be inter-
preted accordingly. Different regimens of dosage and time
intervals might give different results.
Conclusion
We conclude that repeated intravenous injections of
EPI administered according to resuscitation guidelines
during CA, increases APV after the first injection only
despite an increase in CPP after 3 out of 4 EPI injec-
tions. We found no difference in AMSA values at any
measuring point.
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